Changchun Deng

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Howard A. Burris, Ian W. Flinn, Manish R. Patel et al. · The Lancet Oncology · 2018 · 205 citations

Medicine, Oncology, Pharmacology +16

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study

Lorenzo Falchi, Helen Ma, Sandra E. Klein et al. · Blood · 2020 · 185 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +4

Integrating phenotypic and expression profiles to map arsenic-response networks

Astrid C. Haugen, Ryan Kelley, Jennifer B. Collins et al. · Genome biology · 2004 · 184 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Jennifer E. Amengual, Renee Lichtenstein, Jennifer Kimberly Lue et al. · Blood · 2017 · 134 citations · Full text

Life Sciences, Immunology, Oncology +8

The <i>Saccharomyces cerevisiae</i> Kinesin-related Motor Kar3p Acts at Preanaphase Spindle Poles to Limit the Number and Length of Cytoplasmic Microtubules

William S. Saunders, David Hornack, Valerie Lengyel et al. · The Journal of Cell Biology · 1997 · 130 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17